Swedish Orphan Biovitrum Balance Sheet Health
Financial Health criteria checks 4/6
Swedish Orphan Biovitrum has a total shareholder equity of SEK39.0B and total debt of SEK13.7B, which brings its debt-to-equity ratio to 35%. Its total assets and total liabilities are SEK70.1B and SEK31.1B respectively. Swedish Orphan Biovitrum's EBIT is SEK5.8B making its interest coverage ratio 5.3. It has cash and short-term investments of SEK997.0M.
Key information
34.98%
Debt to equity ratio
SEK 13.66b
Debt
| Interest coverage ratio | 5.3x |
| Cash | SEK 997.00m |
| Equity | SEK 39.04b |
| Total liabilities | SEK 31.08b |
| Total assets | SEK 70.12b |
Recent financial health updates
Swedish Orphan Biovitrum (STO:SOBI) Has A Pretty Healthy Balance Sheet
Jan 21
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Jun 24Recent updates
Swedish Orphan Biovitrum AB (publ) Just Recorded A 30% EPS Beat: Here's What Analysts Are Forecasting Next
May 02Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Price In Tune With Earnings
Apr 18Does Swedish Orphan Biovitrum (STO:SOBI) Deserve A Spot On Your Watchlist?
Feb 28Swedish Orphan Biovitrum AB (publ) Just Recorded A 8.0% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 07Swedish Orphan Biovitrum (STO:SOBI) Has A Pretty Healthy Balance Sheet
Jan 21Earnings Tell The Story For Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Dec 30
Innovative Product Launches And Global Expansion Drive Bright Future In Sobi's Portfolio
Expansion of hematology and immunology divisions, with new product launches, drives strong revenue growth and market positioning.Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next
Oct 27Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 19Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Jun 24Financial Position Analysis
Short Term Liabilities: SOBI's short term assets (SEK11.7B) do not cover its short term liabilities (SEK12.0B).
Long Term Liabilities: SOBI's short term assets (SEK11.7B) do not cover its long term liabilities (SEK19.1B).
Debt to Equity History and Analysis
Debt Level: SOBI's net debt to equity ratio (32.4%) is considered satisfactory.
Reducing Debt: SOBI's debt to equity ratio has reduced from 80.6% to 35% over the past 5 years.
Debt Coverage: SOBI's debt is well covered by operating cash flow (54.4%).
Interest Coverage: SOBI's interest payments on its debt are well covered by EBIT (5.3x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/13 20:02 |
| End of Day Share Price | 2025/06/13 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Swedish Orphan Biovitrum AB (publ) is covered by 30 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Xue Chen | Barclays |
| Rosie Turner | Barclays |